Sensus Healthcare to Announce Second Quarter 2016 Results on August 4, 2016
BOCA RATON, Fla., Aug. 2, 2016 — Sensus Healthcare, Inc. (NASDAQ: SRTS; SRTSW), a medical device company specializing in the treatment of non-melanoma skin cancers and other skin conditions, such as keloids, with superficial radiation therapy, today provided a reminder that it will report its second quarter 2016 financial results on Thursday, August 4, 2016 […]
Sensus Healthcare, Inc. Names Anthony Petrelli to its Board of Directors
– Over 40 Years in Investment Banking – Extensive Regulatory and Securities Advisory Experience BOCA RATON, Fla., Aug. 2, 2016 — Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the treatment of non-melanoma skin cancers and other skin conditions, such as keloids, with superficial radiation therapy, today announced the appointment of Anthony […]
Sensus Healthcare, Inc. Units Separate; Trading of Common Stock and Warrants Commences
BOCA RATON, Fla., July 25, 2016 — Sensus Healthcare, Inc. (NASDAQ: SRTSU), a medical device company specializing in the treatment of non-melanoma skin cancers and other skin conditions, such as keloids, with superficial radiation therapy, today reported the separation of the 2,300,000 units issued in its underwritten initial public offering in accordance with their terms. […]
Sensus Healthcare, Inc. Announces Separation of Units Sold in IPO
BOCA RATON, Fla., July 21, 2016 — Sensus Healthcare, Inc. (NASDAQ: SRTSU), a medical device company specializing in the treatment of non-melanoma skin cancers and other skin conditions, such as keloids, with superficial radiation therapy, today announced that the 2,300,000 units issued in its underwritten initial public offering will separate in accordance with their terms […]
Sensus Healthcare, Inc. Announces Completion of Initial Public Offering, including Underwriters’ Exercise of Over-Allotment Option in Full
BOCA RATON, Fla., June 8, 2016 — Sensus Healthcare, Inc. (NASDAQ: SRTSU), a medical device company specializing in the treatment of non-melanoma skin cancers and other skin conditions, such as keloids, with superficial radiation therapy, today announced the completion of its initial public offering of 2,300,000 units at a public offering price of $5.50 per […]
